Getinge AB (publ) logo

Getinge AB (publ)

GETI-B.ST
62
Medical - Devices · Healthcare
Price
kr 196.25
+7.70 (+4.08%)
Market Cap
kr 53.45B
Exchange
Stockholm Stock Exchange
Winston Score
62
Winston looking curious
Winston is curious
A decent business — some strong pillars, some weaker.

Winston Score between 40 and 70. The stock passes some quality checks but not all.

Getinge is a Swedish medical technology company that makes equipment used in hospitals and life science labs. Its main products include sterilization systems, surgical tables and lights, ventilators, heart-lung machines, and intensive care equipment. Hospitals, clinics, and pharmaceutical manufacturers around the world are its primary customers.

The company earns revenue by selling capital equipment and then generating recurring income from consumables, service contracts, and software tied to that installed base. Getinge operates globally, with strong presence in Europe and North America, and reported roughly 34 billion Swedish kronor in annual sales. Its competitive position rests on long-standing customer relationships and the high cost of switching out critical hospital infrastructure once installed. The key risk facing the business is its ongoing effort to resolve past quality and regulatory issues with the U.S. Food and Drug Administration, which previously restricted some product shipments and continues to require close attention to manufacturing compliance.

Winston Score History

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
48.4%
Healthy — 48.4% gross margin
Operating Margin
9.9%
Modest — 9.9% operating margin
ROCE
1.8%
Weak — 1.8% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-4.1%
Shrinking sales (-4.1% YoY)
EPS YoY
+59.6%
Earnings growing fast (59.6% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency
8/8 quarters
Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
194%
Turns 194% of profit into real cash
FCF Margin
9.7%
Modest free cash flow (9.7%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.31
Conservative — low debt load (0.31)
Interest Cover
6.85x
Adequate interest coverage (6.8x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio
23.1x
Growth-priced — P/E 23.1

P/E above the market average. People are paying up for expected growth.

P/E vs Forward
+8.2
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (23.1 → 14.9)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield
2.44%
Moderate income — 2.44% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend Growth
+89.5%
Dividend growing fast (89.5% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial